98%
921
2 minutes
20
High reliability and creativity remain key goals for AI-driven de novo molecule design. In this work, we propose a fragment-driven progressive alternating diffusion (FDPAD) framework in a coarse-to-fine generation mode. By modeling molecules as fragment-structured graphs, FDPAD entails a progressive discrete diffusion process by randomly walking some sequences of fragment-structured units (FSU), thereby mitigating combinatorial complexities and facilitating the synthesis of intricate macroscopic structures. To delve deeper internal structures of FSU, we design two distinct diffusion processes: the conditioned fragment diffusion (CFD) and the inter-fragment bond diffusion (IBD). In CFD, a string-based diffusion probability model is proposed to enrich the diversity of fragments, leveraging the partially-generated molecule as condition. And in IBD, a graph-based diffusion model upon bond-related atom graph is proposed to boost the prediction of intricate chemical bond connections among molecular fragments. Through the interleaving of CFD and IBD processes, our model outperforms state-of-the-art algorithms in de novo molecular generation, particularly in generating novel and unique molecules.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/TCBBIO.2025.3598112 | DOI Listing |
IEEE Trans Comput Biol Bioinform
August 2025
High reliability and creativity remain key goals for AI-driven de novo molecule design. In this work, we propose a fragment-driven progressive alternating diffusion (FDPAD) framework in a coarse-to-fine generation mode. By modeling molecules as fragment-structured graphs, FDPAD entails a progressive discrete diffusion process by randomly walking some sequences of fragment-structured units (FSU), thereby mitigating combinatorial complexities and facilitating the synthesis of intricate macroscopic structures.
View Article and Find Full Text PDFCurr Opin Drug Discov Devel
May 2005
Locus Pharmaceuticals Inc, 4 Valley Square, 512 Township Line Road, Blue Bell, PA 19422, USA.
A reliable and accurate method for the computational design of novel drug candidates has been a passionate pursuit of the pharmaceutical industry. Such technology would dramatically improve the efficiency of drug discovery by quickly and inexpensively providing potent molecules that can be further prioritized for synthesis based on characteristics such as patentability, specific protein-ligand interactions, ease of chemical synthesis, protein selectivity and pharmacological considerations. Described herein is the progress made at Locus Pharmaceuticals Inc toward achieving this ideal with a fragment-driven, computationally directed approach to small-molecule discovery.
View Article and Find Full Text PDF